{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T12:31:45Z","timestamp":1724416305281},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T00:00:00Z","timestamp":1394409600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087799","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T16:29:21Z","timestamp":1394468961000},"page":"e87799","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes"],"prefix":"10.1371","volume":"9","author":[{"given":"Cheol-Young","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Goo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junghyun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Joon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Beom","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,3,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(06)69703-1","article-title":"Epidemic obesity and type 2 diabetes in Asia","volume":"368","author":"KH Yoon","year":"2006","journal-title":"Lancet"},{"key":"ref2","unstructured":"Task Force Team For Basic Statistical Study of Korean Diabetes Mellitus (2007) Report of Task Force Team For Basic Statistical Study of Korean Diabetes Mellitus: Diabetes in Korea 2007. 1st ed. Seoul, Goldfishery."},{"key":"ref3","unstructured":"Statistics Korea: 2009 statistical results about cause of death. Available: http:\/\/www.index.go.kr<\/ext-link> (updated 2011 Aug 5)."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"RR Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"SE Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.2337\/diacare.26.8.2238","article-title":"Insulin 70\/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis","volume":"26","author":"S Schwartz","year":"2003","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2337\/dc06-0564","article-title":"Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea","volume":"29","author":"C Triplitt","year":"2006","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2337\/dc06-1712","article-title":"Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes","volume":"30","author":"AI Vinik","year":"2007","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","article-title":"Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients","volume":"29","author":"J Rosenstock","year":"2006","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1463-1326.2008.00980.x","article-title":"Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7\u20138% HbA1c levels. The TULIP study","volume":"11","author":"JF Blickl\u00e9","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diabres.2007.03.021","article-title":"Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study","volume":"78","author":"R Houlden","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4158\/EP09281.OR","article-title":"Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"16","author":"LF Meneghini","year":"2010","journal-title":"Endocr Pract"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"MC Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJM199211123272005","article-title":"Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus","volume":"327","author":"H Yki-J\u00e4rvinen","year":"1992","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2337\/diacare.18.3.307","article-title":"Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients","volume":"18","author":"CC Chow","year":"1995","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-130-5-199903020-00002","article-title":"Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial","volume":"130","author":"H Yki-J\u00e4rvinen","year":"1999","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4093\/dmj.2011.35.5.431","article-title":"Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2011 clinical practice guidelines for type 2 diabetes in Korea","volume":"35","author":"SH Ko","year":"2011","journal-title":"Diabetes Metab J"},{"key":"ref18","first-page":"S11","article-title":"Standards of medical care in diabetes-2011","volume":"34 Suppl 1","year":"2011","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/dc08-9026","article-title":"Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association","volume":"32","author":"JS Skyler","year":"2009","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.7326\/0003-4819-154-8-201104190-00007","article-title":"Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials","volume":"154","author":"F Ismail-Beigi","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-155-5-201109060-00025","article-title":"Individualizing Glycemic Targets in Type 2 Diabetes Mellitus","volume":"155","author":"D Aron","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial","volume":"138","author":"A Fritsche","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:48:21Z","timestamp":1540219701000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087799"}},"subtitle":[],"editor":[{"given":"T. Mark","family":"Doherty","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,10]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087799","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,10]]}}}